Phase III EPIC Trial of Ponatinib versus Imatinib in Newly Diagnosed CML in Chronic Phase


Phase III EPIC Trial of Ponatinib versus Imatinib in Newly Diagnosed CML in Chronic Phase
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Jorge E Cortes, MD (1/14/15)
Lipton JH et al. Epic: A Phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML). Proc ASH 2014;Abstract 519.

Dr Cortes is DB Lane Cancer Research Distinguished Professor for Leukemia Research and Deputy Chairman and Section Chief of AML and CML in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.